BR112017000398A2 - composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit. - Google Patents

composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.

Info

Publication number
BR112017000398A2
BR112017000398A2 BR112017000398A BR112017000398A BR112017000398A2 BR 112017000398 A2 BR112017000398 A2 BR 112017000398A2 BR 112017000398 A BR112017000398 A BR 112017000398A BR 112017000398 A BR112017000398 A BR 112017000398A BR 112017000398 A2 BR112017000398 A2 BR 112017000398A2
Authority
BR
Brazil
Prior art keywords
heartworm
immitis
treating
kit
infection caused
Prior art date
Application number
BR112017000398A
Other languages
English (en)
Inventor
Regina Heckeroth Anja
Pierre Alain Chassaing Christophe
Lutz Jürgen
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112017000398A2 publication Critical patent/BR112017000398A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

esta invenção está relacionada aos compostos e sais que são, de modo geral, úteis como agentes para tratar uma infecção causada por dirofilaria immitis. esta invenção refere-se, também, aos tratamentos compreendendo a administração dos compostos e sais aos animais que necessitam dos tratamentos.
BR112017000398A 2014-07-11 2015-07-10 composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit. BR112017000398A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176733 2014-07-11
PCT/EP2015/065868 WO2016005576A1 (en) 2014-07-11 2015-07-10 Use of anthelmintic agents against dirofilaria immitis

Publications (1)

Publication Number Publication Date
BR112017000398A2 true BR112017000398A2 (pt) 2018-01-23

Family

ID=51167758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000398A BR112017000398A2 (pt) 2014-07-11 2015-07-10 composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.

Country Status (7)

Country Link
US (2) US10010538B2 (pt)
EP (1) EP3177291A1 (pt)
JP (1) JP2017519802A (pt)
CN (1) CN106659720A (pt)
AU (1) AU2015286634A1 (pt)
BR (1) BR112017000398A2 (pt)
WO (1) WO2016005576A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3448859T1 (sl) 2017-03-20 2020-02-28 Forma Therapeutics, Inc. Sestavki pirolopirola kot aktivatorji piruvat kinaze (PKR)
CA3068254A1 (en) 2017-06-20 2018-12-27 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213612C (en) 1995-02-24 2008-07-15 Novartis Ag Composition for controlling parasites
TW200938203A (en) 2007-12-17 2009-09-16 Intervet Int Bv Anthelmintic agents and their use
TW201041868A (en) 2009-03-20 2010-12-01 Intervet Int Bv Anthelmintic agents and their use
TW201111358A (en) 2009-06-18 2011-04-01 Intervet Int Bv Anthelmintic agents and their use
EP2468096A1 (en) * 2010-12-21 2012-06-27 Intervet International BV Anthelmintic combinations
AP3965A (en) 2012-11-20 2016-12-24 Merial Ltd Anthelminitic compounds and compositions and method of using thereof

Also Published As

Publication number Publication date
WO2016005576A1 (en) 2016-01-14
AU2015286634A1 (en) 2017-01-19
US20180280367A1 (en) 2018-10-04
EP3177291A1 (en) 2017-06-14
JP2017519802A (ja) 2017-07-20
CN106659720A (zh) 2017-05-10
US20170202816A1 (en) 2017-07-20
US10010538B2 (en) 2018-07-03

Similar Documents

Publication Publication Date Title
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
BR112017000398A2 (pt) composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
CO2017007671A2 (es) Composiciones para modular la expresión de c9orf72
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
EA201790398A1 (ru) Способы лечения заболевания печени
CY1122305T1 (el) Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
BR112018013522A2 (pt) compostos inibidores de metaloenzima
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EA201791140A1 (ru) Противомикробные составы и соответствующие методы обработки пищевых продуктов и поверхностей
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
EA201790091A1 (ru) Лечение тяжелой гипертриглицеридемии
NI201700057A (es) Método para tratar, prevenir o reducir el riesgo de infección cutánea
EA201890188A1 (ru) Новый бициклический липолантипептид, его получение и применение в качестве противомикробного средства
BR112017025316A2 (pt) estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
CY1124229T1 (el) Συνδυασμος τραζοδονης και γκαμπαπεντινης για την αντιμετωπιση του πονου

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements